Dr. Yorell Manon Matos Launches National Grant to Address Economic Challenges in Healthcare
SIOUX FALLS, S.D. - The Dr. Yorell Manon Matos Grant for Healthcare Students is now officially accepting applications for its 2025 cycle, offering financial support to undergraduate students committed to transforming the future of healthcare. This national initiative is designed to recognize and support high-achieving individuals pursuing degrees in medicine, nursing, public health, and other healthcare-related fields.
Founded by Dr. Yorell Manon Matos, a respected hand and microsurgeon based in South Dakota, this grant initiative reflects his dedication to developing the next generation of medical professionals. With a distinguished academic and professional background, including training at Dartmouth Medical School, Tufts University, and the Christine M. Kleinert Institute Dr. Yorell Manon Matos brings years of clinical excellence and educational leadership to this initiative.
The Dr. Yorell Manon Matos Grant for Healthcare Students is open to undergraduate students enrolled at accredited universities or colleges across the United States. Eligible applicants must be pursuing a degree in healthcare or a closely related field and must demonstrate academic excellence with a minimum GPA of 3.0. Additionally, applicants should show a clear commitment to improving healthcare systems through innovative thinking, policy awareness, and a dedication to service.
At the heart of the application process is a required essay responding to the prompt: 'Discuss the economic challenges in healthcare today. How do you think innovations and policies could improve both affordability and quality of care for patients?' The essay should be between 1,000 and 1,500 words and must reflect critical analysis, originality, and a clear understanding of the economic complexities within the healthcare system.
Applicants are also required to submit a brief cover letter alongside their essay. Submissions must be sent via email to apply@dryorellmanonmatosgrant.com by August 15, 2025. The winning applicant will be announced on September 15, 2025, and will receive a one-time financial award to support their academic journey in healthcare.
Through this grant, Dr. Yorell Manon Matos seeks to encourage thoughtful engagement with pressing healthcare issues and to support students who are determined to make a lasting impact in their respective fields. His ongoing clinical work at the Center for Neuroscience, Orthopaedics, and Spine in South Dakota continues to inspire his commitment to mentorship, education, and patient care.
This initiative builds on Dr. Yorell Manon Matos' career-long dedication to excellence in healthcare delivery and academic leadership. By launching the grant, Dr. Yorell Manon Matos aims to create a meaningful opportunity for emerging healthcare professionals to deepen their understanding of healthcare economics while receiving support for their academic endeavors.
The Dr. Yorell Manon Matos Grant for Healthcare Students reflects a broader mission to address systemic healthcare challenges by investing in the potential of students who aspire to lead, heal, and innovate. With healthcare continuing to evolve rapidly, programs like this serve as a critical support system for young professionals preparing to meet future demands.
For more details on the grant and application guidelines, students are encouraged to visit the official website at https://dryorellmanonmatosgrant.com/.
Media Contact
Company Name: Dr. Yorell Manon Matos Grant for Healthcare Students
Contact Person: Dr. Yorell Manon Matos
Email: Send Email
City: SIOUX FALLS
State: South Dakota
Country: United States
Website: https://dryorellmanonmatosgrant.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. 'I am delighted to welcome Martin Steegmaier to Molecular Partners, where his extensive expertise in oncology, business and leadership will provide further impetus to our efforts to deliver unique cancer therapies,' said Patrick Amstutz, Ph.D., CEO of Molecular Partners. 'Martin's experience will be invaluable in leading the research organization and as we continue to innovate and advance our pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation.' Martin Steegmaier joins Molecular Partners from SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies, including as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology. He previously held various positions in pharma partnering and oncology disease areas at Roche, becoming Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich, and at Boehringer Ingelheim in oncology drug discovery. Martin graduated from the Northern Arizona University and holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. Martin Steegmaier, Ph.D., said: 'I'm pleased to join the exceptional team at Molecular Partners and to contribute to pioneering the cutting-edge DARPin therapeutics. I have built up considerable experience in oncology over my career, including developing large molecules at Roche and other organizations, which is directly relevant to the advancement of Molecular Partners' exciting DARPin platforms and pipeline. I am looking forward to working with the team and to driving forward the next generation of DARPin therapeutics for patients with high unmet need.' About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. Tel: +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Globe and Mail
7 hours ago
- Globe and Mail
Dr. Yorell Manon Matos Launches National Grant to Address Economic Challenges in Healthcare
New Opportunity for Undergraduate Students Pursuing Careers in Medicine and Healthcare Fields SIOUX FALLS, S.D. - The Dr. Yorell Manon Matos Grant for Healthcare Students is now officially accepting applications for its 2025 cycle, offering financial support to undergraduate students committed to transforming the future of healthcare. This national initiative is designed to recognize and support high-achieving individuals pursuing degrees in medicine, nursing, public health, and other healthcare-related fields. Founded by Dr. Yorell Manon Matos, a respected hand and microsurgeon based in South Dakota, this grant initiative reflects his dedication to developing the next generation of medical professionals. With a distinguished academic and professional background, including training at Dartmouth Medical School, Tufts University, and the Christine M. Kleinert Institute Dr. Yorell Manon Matos brings years of clinical excellence and educational leadership to this initiative. The Dr. Yorell Manon Matos Grant for Healthcare Students is open to undergraduate students enrolled at accredited universities or colleges across the United States. Eligible applicants must be pursuing a degree in healthcare or a closely related field and must demonstrate academic excellence with a minimum GPA of 3.0. Additionally, applicants should show a clear commitment to improving healthcare systems through innovative thinking, policy awareness, and a dedication to service. At the heart of the application process is a required essay responding to the prompt: 'Discuss the economic challenges in healthcare today. How do you think innovations and policies could improve both affordability and quality of care for patients?' The essay should be between 1,000 and 1,500 words and must reflect critical analysis, originality, and a clear understanding of the economic complexities within the healthcare system. Applicants are also required to submit a brief cover letter alongside their essay. Submissions must be sent via email to apply@ by August 15, 2025. The winning applicant will be announced on September 15, 2025, and will receive a one-time financial award to support their academic journey in healthcare. Through this grant, Dr. Yorell Manon Matos seeks to encourage thoughtful engagement with pressing healthcare issues and to support students who are determined to make a lasting impact in their respective fields. His ongoing clinical work at the Center for Neuroscience, Orthopaedics, and Spine in South Dakota continues to inspire his commitment to mentorship, education, and patient care. This initiative builds on Dr. Yorell Manon Matos' career-long dedication to excellence in healthcare delivery and academic leadership. By launching the grant, Dr. Yorell Manon Matos aims to create a meaningful opportunity for emerging healthcare professionals to deepen their understanding of healthcare economics while receiving support for their academic endeavors. The Dr. Yorell Manon Matos Grant for Healthcare Students reflects a broader mission to address systemic healthcare challenges by investing in the potential of students who aspire to lead, heal, and innovate. With healthcare continuing to evolve rapidly, programs like this serve as a critical support system for young professionals preparing to meet future demands. For more details on the grant and application guidelines, students are encouraged to visit the official website at Media Contact Company Name: Dr. Yorell Manon Matos Grant for Healthcare Students Contact Person: Dr. Yorell Manon Matos Email: Send Email City: SIOUX FALLS State: South Dakota Country: United States Website:
Globe and Mail
8 hours ago
- Globe and Mail
Genetic-Based Longevity Medicine: Enov.one Outperforms AgelessRx in Personalized Healthcare
is redefining personalized medicine by integrating genetics, labs, and wearable data into adaptive, evidence-based treatment plans, outperforming generic telehealth models like AgelessRx. With continuous monitoring, specialized practitioners, and real-time protocol adjustments, it delivers precision care that evolves with each patient's biology. Over the past decade, personalized medicine has shifted from theory to practice. Consumers increasingly expect healthcare tailored to their biology, not one-size-fits-all prescriptions. Platforms at the forefront are blending genetics, lab data, and wearable tech to deliver precision care with outperforming brands like AgelessRx to deliver superior results. Why Generic Telehealth Isn't Enough Most telehealth services still follow the same pattern: short consultations, standard prescriptions, and little follow-up. While convenient, these models leave out key variables like genetic differences, metabolic markers, and lifestyle data, all of which dramatically influence treatment outcomes. This is where differentiates itself. Unlike conventional services that rely heavily on questionnaires, it integrates multiple data sources: genetic files from 23andMe or Ancestry, lab results, and real-time data from wearables like Apple Watch or Fitbit. By combining these inputs, the platform can generate highly personalized treatment plans that adapt as patient data changes. The AgelessRx Comparison AgelessRx has carved out a reputation in longevity-focused telemedicine, but its approach resembles traditional online clinics. Protocols are largely standardized, genetic analysis isn't incorporated, and wearable integration is absent. Consultations often happen asynchronously, with limited depth of review. by contrast, emphasizes continuous monitoring and algorithm-driven adjustments. Treatment effectiveness is tracked in real time, and protocols evolve as new data is added. That feedback loop, genetics plus labs plus wearables, allows for a degree of personalization that basic telehealth platforms simply can't replicate. Evidence-Based Longevity Care One of the challenges in longevity medicine is separating science from hype. positions itself firmly in the evidence-based camp. Compounds like NAD+, glutathione, and methylcobalamin are chosen based on published studies, not wellness trends. Partner pharmacies ensure dosing precision and quality standards, with third-party testing verifying potency and purity. This scientific rigor, paired with continuous adaptation, makes stand out in a crowded field where many players focus more on marketing than measurable outcomes. The Bigger Picture The rise of platforms like reflects a broader shift in healthcare: patients no longer want generic advice or static treatment plans. They expect precision, transparency, and measurable results. While established players like AgelessRx introduced longevity care to a wider audience, next-generation platforms are pushing the field further with advanced data integration and ongoing monitoring. Modern healthcare must embrace technology rather than resist it. Electronic health records, genetic databases, and wearable devices generate unprecedented amounts of health information. Forward-thinking platforms leverage this data effectively while traditional providers struggle with basic electronic systems. Machine learning algorithms identify patterns in complex datasets that overwhelm human analysis capabilities. Genetic variants interact with environmental factors in ways that require computational power to understand fully. Manual review processes simply can't compete with sophisticated algorithmic analysis. Real-time data streams enable dynamic protocol adjustments. Static treatment plans become obsolete when continuous monitoring reveals changing health patterns. Responsive platforms adapt quickly while rigid systems maintain ineffective protocols for months. Professional Network Advantages telemedicine network includes practitioners specifically trained in longevity medicine protocols. General physicians lack specialized knowledge about anti-aging compounds and optimization strategies. This expertise gap leads to conservative prescribing and missed opportunities for meaningful health improvements. Partner pharmacies understand compounding requirements for specialized formulations. Chain pharmacies often can't fulfill customized prescriptions or handle sensitive compounds properly. Specialized fulfillment networks ensure treatment quality and reliable availability. Geographic limitations disappear with comprehensive telemedicine platforms. Rural areas lack longevity medicine specialists completely. Remote consultations provide access to expertise regardless of location while maintaining personalized attention that generic platforms can't match. Making the Switch Consumers deserve healthcare platforms that match their sophistication and health goals. Generic approaches waste time and money while delivering mediocre results. Precision medicine platforms like represent the future of optimization-focused healthcare. Getting started requires genetic testing if existing data isn't available. Recent lab work provides current health status information. Wearable devices should be connected to capture lifestyle data. The platform handles analysis and protocol development automatically. Those ready to experience genuinely personalized longevity medicine should explore comprehensive platform. Contact their team to discuss individual health goals and learn how genetic-based interventions can optimize wellness and extend healthy lifespan. The technology exists today to revolutionize personal healthcare - the question becomes whether to embrace these advances now or wait for competitors to catch up. Media Contact Company Name: Enovone, Inc. Contact Person: Enov One Email: Send Email Country: United States Website:
